NR4A1 and breast cancer: Lafky et al. examined sEGFR levels using an acridinium-linked immunosorbent assay in 64 hormone receptor positive metastatic BC patients before start of a new treatment and compared them to 43 matched healthy women with no differences found between the two groups18.